Lilly's Jaypirca (pirtobrutinib) recommended by CHMP for approval in the European Union for adults with chronic lymphocytic leukemia (CLL) across all lines of therapy
Go back to Lilly's Jaypirca (pirtobrutinib) recommended by CHMP for approval in the European Union for adults with chronic lymphocytic leukemia (CLL) across all lines of therapy| Lilly (Eli) & Co. (NYSE: LLY) | Delayed: 1208.12 +80.43 (7.13%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $1127.69 | 52 Week High | $88.16 | |||
| Open | $1128.80 | 52 Week Low | $67.88 | |||
| Day High | $1215.74 | P/E | 279.66 | |||
| Day Low | $1128.00 | EPS | $4.32 | |||
| Volume | 7,724,615 | |||||
